EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of peanut epicutaneous immunotherapy in patients with atopic comorbidities

Carla M Davis, Lars Lange, Kirsten Beyer, David M Fleischer, Lara Ford, Gordon Sussman, Roxanne C Oriel, Jacqueline A Pongracic, Wayne Shreffler, Katharine J Bee, Dianne E Campbell, Todd D Green und 3 weitere

Journal of Allergy and Clinical Immunology: Global · 2023-02 · 2 (1) · 69-75

DOI: 10.1016/j.jacig.2022.07.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology: Global, 2023-02. Verfasst von Carla M Davis und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Immunology, Allergy and Retrovirology Section, Baylor College of Medicine, Houston, Tex. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi, Financial Markets Foundation for Children, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Co-occurring atopic conditions are common in children with peanut allergy. As such, it is important to examine the safety and efficacy of epicutaneous immunotherapy with Viaskin Peanut 250 μg patch (VP250) in peanut-allergic children with these conditions.

Objective

We sought to compare efficacy and safety of VP250 versus placebo in peanut-allergic children with/without ongoing atopic conditions at baseline, including asthma, atopic dermatitis/eczema, or concomitant food allergy.

Methods

A subgroup analysis of peanut-allergic children aged 4 to 11 years enrolled in PEPITES (12 months) and REALISE (6 months) randomized, placebo-controlled, phase 3 trials was conducted. The efficacy outcome measure was the difference in prespecified responder rate between placebo and VP250 groups at month 12 based on eliciting dose of peanut protein using double-blind, placebo-controlled food challenge in PEPITES. Safety profiles were evaluated by baseline concomitant disease subgroup in all randomized subjects who received 1 or more dose of the study drug in PEPITES and REALISE pooled data.

Results

Responder rates were significantly (P < .05, all comparisons) greater with VP250 compared with placebo treatment regardless of whether subjects had other atopic conditions. Safety and tolerability profiles were generally similar across subgroups, with no new safety concerns detected. A trend for both higher responder rates and rates of local reactions was observed in subjects with baseline atopic dermatitis versus those without. In subjects with concomitant food allergy at baseline, higher rates of treatment-emergent adverse events, but not study discontinuations or overall rates of anaphylaxis, were observed.

Conclusions

The results support the safety and efficacy of VP250 for treating peanut-allergic children with or without concomitant atopic conditions.

Schlagwörter

Stichwörter der Autor:innen

Epicutaneous immunotherapyViaskin Peanutchildrenconcomitant atopic conditionsdesensitizationfood allergyimmunotherapypeanut allergy

Autor:innen und Institutionen

  • Department of Pediatrics, Immunology, Allergy and Retrovirology Section, Baylor College of Medicine, Houston, Tex.
  • Department of Pediatrics, St. Marien Hospital Bonn, Bonn, Germany.
  • Department of Pediatric Pneumology, Immunology and Intensive Care Medicine, Charité Universitatsmedizin Berlin, Berlin, Germany.
  • Children's Hospital Colorado, University of Colorado Denver School of Medicine, Aurora, Colo.
  • Department of Allergy and Immunology, The Children's Hospital at Westmead, Sydney, Australia.
  • Discipline of Child and Adolescent Health, University of Sydney School of Medicine, Sydney, Australia.

Förderung

  • Sanofi
  • Financial Markets Foundation for Children
  • National Institutes of Health
  • Aimmune Therapeutics
  • Nutricia North America
  • National Health and Medical Research Council
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Davis, C. M., Lange, L., Beyer, K., Fleischer, D. M., Ford, L., Sussman, G., Oriel, R. C., Pongracic, J. A., Shreffler, W., Bee, K. J., Campbell, D. E., Green, T. D., Lambert, R., Peillon, A., & Bégin, P. (2023). Efficacy and safety of peanut epicutaneous immunotherapy in patients with atopic comorbidities. Journal of Allergy and Clinical Immunology: Global, 2(1), 69-75. https://doi.org/10.1016/j.jacig.2022.07.009

Vancouver

Davis CM, Lange L, Beyer K, Fleischer DM, Ford L, Sussman G, et al. Efficacy and safety of peanut epicutaneous immunotherapy in patients with atopic comorbidities. Journal of Allergy and Clinical Immunology: Global. 2023;2(1):69-75. doi:10.1016/j.jacig.2022.07.009

BibTeX
@article{Davis2023,
  author = {Davis, Carla M and Lange, Lars and Beyer, Kirsten and Fleischer, David M and Ford, Lara and Sussman, Gordon and Oriel, Roxanne C and Pongracic, Jacqueline A and Shreffler, Wayne and Bee, Katharine J and Campbell, Dianne E and Green, Todd D and Lambert, Romain and Peillon, Aurélie and Bégin, Philippe},
  title = {Efficacy and safety of peanut epicutaneous immunotherapy in patients with atopic comorbidities},
  journal = {Journal of Allergy and Clinical Immunology: Global},
  year = {2023},
  volume = {2},
  number = {1},
  pages = {69--75},
  doi = {10.1016/j.jacig.2022.07.009}
}
Kostenlos starten →